News

Russia offers to supply anti-Covid drugs to India

G Naga Sridhar Hyderabad | Updated on July 27, 2020 Published on July 27, 2020

Russia has offered to supply three anti-Covid drugs to India, and said that pharma companies can forge trade pacts for import.

Russia has domestically developed a few drugs and also registered a number of foreign drugs for the treatment of Covid-19. “Out of these drugs, the Russian Ministry of Health and its industry has offered to supply supply three indigenously manufactured anti-Covid drugs which are showing positive results in Russia to Indian companies,'' Uday Bhaskar, Director General, Pharmaceutical Exports Promotion Council (Pharmexcil) said in a communication to the pharma companies.

The drugs being offered are Favipiravir (trade name Avifavir), manufactured by Research Institute of Chemical Diversity, Russia; Olokizumab ( trade name Artlegia), a humanised monoclonal antibody that directly blocks the inflammatory mediator, manufactured by R-Pharm; and Levilimab ( trade name Llsira) recommended for patients suffering from ‘cytokine storm’.

Members of the Pharmaceutical Export Promotion Council of India (Pharmexcil) who have substantial commercial interest can approach the Russian manufacturers of these three drugs through contacts provided by Pharmexcil, Bhaska said.

Import of any drugs into India needs to adhere to the provisions of the Drugs and Cosmetics Act,1940 and Rules, 1945.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on July 27, 2020
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.